Findings

What do systematic reviews say?

51 questions · 51 findings · 21 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 6 · 11.8%GRADE not reported 3 · 5.9%Very low 21 · 41.2%Low 10 · 19.6%Moderate 8 · 15.7%High 3 · 5.9%

Macrolides vs tetracycline

All‐cause mortality · patients with chronic obstructive pulmonary disease

1 finding from 1 review

Head‐to‐head oral prophylactic antibiotic therapy for chronic obstructive pulmonary disease 2019 · Cochrane Headline outcomes only
no estimate extracted
1 study · 50 participants
GRADE not reported

Quinolone vs tetracycline

All‐cause mortality · patients with chronic obstructive pulmonary disease

1 finding from 1 review

Head‐to‐head oral prophylactic antibiotic therapy for chronic obstructive pulmonary disease 2019 · Cochrane Headline outcomes only
no estimate extracted
1 study · 50 participants
GRADE not reported

Macrolides vs placebo

All‐cause mortality · adults with bronchiectasis

1 finding from 1 review

Macrolide antibiotics for bronchiectasis 2018 · Cochrane Headline outcomes only
no estimate extracted
7 studies · 540 participants
Low

Monotherapy vs combination therapy

All‐cause mortality; · Ventilator‐associated pneumonia

Monotherapy showed no clear difference in all‐cause mortality; compared with combination therapy (moderate certainty).

1 finding from 1 review

Antibiotics for ventilator‐associated pneumonia 2016 · Cochrane Headline outcomes only
OR 0.97 [0.73, 1.3]
4 studies · 1163 participants
Moderate

Carbapenems vs non‐carbapenems

All‐cause mortality; · Ventilator‐associated pneumonia

Carbapenems showed no clear difference in all‐cause mortality; compared with non‐carbapenems (moderate certainty).

1 finding from 1 review

Antibiotics for ventilator‐associated pneumonia 2016 · Cochrane Headline outcomes only
OR 0.59 [0.3, 1.19]
1 study · 253 participants
Moderate

Intervention not reported

All‐cause mortality · patients with a recent BSF independent of the presence or severity of CSF leakage

The intervention showed no clear difference in all‐cause mortality (moderate certainty).

1 finding from 1 review

Antibiotic prophylaxis for preventing meningitis in patients with basilar skull fractures 2015 · Cochrane Headline outcomes only
OR 1.68 [0.41, 6.95]
4 studies · 208 participants
Moderate

Isoniazid vs no treatment

All‐cause mortality · kidney transplant recipients

Isoniazid showed no clear difference in all‐cause mortality compared with no treatment (low certainty).

1 finding from 1 review

Antibiotic prophylaxis for preventing post solid organ transplant tuberculosis 2014 · Cochrane Headline outcomes only
RR 1.39 [0.7, 2.78]
3 studies · 558 participants
Low

Cefazolin plus amikacin vs vancomycin plus amikacin

All‐cause mortality maximum · newborns with late‐onset sepsis

It is very uncertain whether cefazolin plus amikacin changes all‐cause mortality maximum compared with vancomycin plus amikacin (very low certainty).

1 finding from 1 review

Antibiotic regimens for late‐onset neonatal sepsis 2021 · Cochrane Headline outcomes only
RR 0.7 [0.29, 1.66]
1 study · 109 participants
Very low

Vancomycin plus gentamicin vs vancomycin plus aztreonam

All‐cause mortality maximum · newborns with late‐onset sepsis

It is very uncertain whether vancomycin plus gentamicin changes all‐cause mortality maximum compared with vancomycin plus aztreonam (very low certainty).

1 finding from 1 review

Antibiotic regimens for late‐onset neonatal sepsis 2021 · Cochrane Headline outcomes only
RR 0.65 [0.2, 2.13]
1 study · 81 participants
Very low

Ticarcillin plus clavulanic acid vs flucloxacillin and gentamicin

All‐cause mortality maximum · newborns with late‐onset sepsis

It is very uncertain whether ticarcillin plus clavulanic acid changes all‐cause mortality maximum compared with flucloxacillin and gentamicin (very low certainty).

1 finding from 1 review

Antibiotic regimens for late‐onset neonatal sepsis 2021 · Cochrane Headline outcomes only
RR 0.2 [0.01, 3.82]
1 study · 28 participants
Very low

Cloxacillin plus amikacin vs cefotaxime plus gentamicin

All‐cause mortality maximum · newborns with late‐onset sepsis

It is very uncertain whether cloxacillin plus amikacin changes all‐cause mortality maximum compared with cefotaxime plus gentamicin (very low certainty).

1 finding from 1 review

Antibiotic regimens for late‐onset neonatal sepsis 2021 · Cochrane Headline outcomes only
RR 0.38 [0.11, 1.27]
1 study · 90 participants
Very low

Meropenem vs usual care

All‐cause mortality maximum · newborns with late‐onset sepsis

It is very uncertain whether meropenem changes all‐cause mortality maximum compared with standard care (very low certainty).

1 finding from 1 review

Antibiotic regimens for late‐onset neonatal sepsis 2021 · Cochrane Headline outcomes only
RR 1.42 [0.56, 3.62]
1 study · 271 participants
Very low